Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

263.04
+1.270.49%
Post-market: 262.57-0.4700-0.18%19:59 EDT
Volume:5.12M
Turnover:1.34B
Market Cap:464.89B
PE:74.31
High:264.81
Open:260.00
Low:257.80
Close:261.77
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.13
T/O Rate:0.29%
Dividend:6.83
Dividend Rate:2.60%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-78.33
PE(LYR):111.46

Loading ...

Abbvie Exec Says Will Present Late-Stage Data for Blood Cancer Drug Etentamig at International Myeloma Society Meeting Later in September - Conf Call

THOMSON REUTERS
·
Yesterday

Abbvie Exec Says Existing Portfolio Provides 'Clear Line of Sight' to Very Strong Growth Well into Next Decade - Conf Call

THOMSON REUTERS
·
Yesterday

Abbvie Exec Says Apogee Fits 'Very Nicely' with Its Business Development Approach - Conf Call

THOMSON REUTERS
·
Yesterday

Abbvie Exec Says Plans to Start Enrolling Apogee's Zumilokibart This Year, Targets Launch in Early 2030 - Conf Call

THOMSON REUTERS
·
Yesterday

Abbvie Exec Says Tavapadon U.S. Launch Expected to Have 'Slower Burn' Due to Timing of Medicare Reimbursement - Conf Call

THOMSON REUTERS
·
Yesterday

Testosterone Scripts for Women Rise, Along with Denials and Delays

Reuters
·
Yesterday

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

TIPRANKS
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

AbbVie Announces Q4 2026 Dividend of R$ 0.37 Per Unit, Payable Nov. 23

Reuters
·
Sep 12

AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV

TIPRANKS
·
Sep 12

Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)

TIPRANKS
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Nov. 16 to Holders of Record Oct. 15

MT Newswires Live
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10